Allergy CE-Mark and first Purchase Order

RNS Number : 0735C
Omega Diagnostics Group PLC
27 September 2018
 

 

Omega Diagnostics Group PLC

("Omega" or the "Company")

 

Allergy CE-Mark and first Purchase Order

 

Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that it has CE-Marked five additional allergens, extending the menu to 58 allergens which can be run on the fully automated IDS Instrument.

 

These allergens will be supplied to IDS under the global distribution agreement announced on 20 April 2018.  Ongoing investment to increase the menu is supported by the research and development grant of up to £1.8 million, which the Company secured from Scottish Enterprise in August 2016.

 

The Company also confirms that commercialisation activities with IDS are proceeding to plan and that it has received its first purchase order which it will supply by the end of October. The size of the order is in line with the Company's expectation, whereby sales are expected to be modest during the initial launch phase.

 

 

 

Contacts:

 

Omega Diagnostics Group PLC                         

Tel: 01259 763 030

Colin King, Chief Executive                             

www.omegadiagnostics.com

Kieron Harbinson, Group Finance Director


                                                  

 

finnCap Ltd                                              

Tel: 020 7220 0500

Geoff Nash/James Thompson (Corporate Finance)


Camille Gochez (Corporate Broking)




Walbrook PR Limited

Tel: 020 7933 8780 or omega@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCLFMFTMBITBJP
UK 100

Latest directors dealings